Organization · Corporate Venture Capital
M Ventures
M Ventures is the corporate venture capital fund of Merck KGaA, based in Amsterdam, Netherlands. It invests in biotechnology and technology companies that align with Merck's strategic interests in healthcare, life sciences, and electronics.
Overview
What M Ventures does
What M Ventures is
M Ventures is the corporate venture capital fund of Merck KGaA, based in Amsterdam, Netherlands. It invests in biotechnology and technology companies that align with Merck's strategic interests in healthcare, life sciences, and electronics.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Corporate Venture Capital
- Founded
- Founded in 2009
- Approximate age
- About 17 years
- Structured capabilities
- Funder
- Last reviewed
- May 5, 2026
Official channels
Find M Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
M Ventures as a funder
Investment thesis
M Ventures invests in visionary companies at the intersection of scientific breakthrough and commercial potential, focusing on healthcare, life science, and electronics.
Focus narrative
M Ventures focuses on investing in companies innovating in healthcare drug development, life science tools, electronics, and frontier technology & sustainability. The fund seeks to back visionary companies that can deliver both strategic and financial returns, addressing significant challenges in these sectors.
Value beyond capital
M Ventures provides strategic support to its portfolio companies by leveraging the resources and expertise of Merck KGaA. This includes access to industry knowledge, potential partnerships, and a network that can facilitate growth and innovation in the healthcare and technology sectors.
Focus and fit
- Stages
- Seed · Series A · Series B · Series C
- Regions
- Global · North America · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 111
Portfolio context
M Ventures has a diverse portfolio that includes notable companies such as Actithera, which focuses on radiopharmaceuticals; Ambrx, engaged in biopharmaceutical development; Calypso Biotech, developing monoclonal antibodies for immune pathologies; and ImmuneBridge, working on allogeneic immunotherapies for cancer. Other portfolio companies include LabGenius, specializing in drug discovery, and Trimtech Therapeutics, which develops small molecule degraders for neurodegenerative diseases.
Common questions
What to know about M Ventures
Upseed classifies M Ventures under the Corporate Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 5, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.